Aging Population

Investment Thesis

The 65+ demographic cohort is the fastest-growing age group in the U.S., Europe, Japan, and increasingly China, and is the highest per-capita consumer of medical services, surgical procedures, and prescription drugs. This demand is structural and irreversible over any investment horizon relevant to equity investing. Healthcare spending as a percentage of GDP is projected to continue rising regardless of policy environment, supporting consistent volume growth for medical device and diagnostics companies exposed to the aging cohort.

Theme Score Breakdown

Aging Population drops to high Moderate+ despite having the most irreversible underlying trend in the library — durability earns a maximum 15 because the 65+ cohort will grow deterministically regardless of any policy or market event. The investment translation is weaker than the demographic strength: government reimbursement compression is an active headwind, GLP-1 drugs are materially disrupting orthopedic and bariatric procedure volumes in real time, and the demographic tailwind has been known and priced into defensive healthcare valuations for decades. The theme is a steady, reliable compounder rather than a dynamic structural break — and the rating reflects that honest distinction.

Key Risks

• Drug pricing regulation and government reimbursement compression reducing ASPs
• GLP-1 drugs reducing obesity-related procedure volumes (joint replacement, bariatric surgery)
• Healthcare policy uncertainty affecting coverage and reimbursement rates
• Demographic dividend already partially priced into medical device valuations